



NEWS RELEASE

FOR IMMEDIATE RELEASE

SeptRx® Intrapocket PFO Occluder (IPO) will be presented from the podium at “EuroPCR 2012”

SeptRx® IPO is designed to close “hole in the heart” defects and lower the risk of stroke, the second-leading cause of death worldwide

SeptRx® IPO technology to be presented at the session, “Cardiovascular Innovation Pipeline,” on Wednesday, May 16th, 16:05 / 4:05 p.m. CET, Room 351, Le Palais des Congrès de Paris

FREMONT, Calif., May 10, 2012 — [SeptRx, Inc.](#), an emerging medical device company, announced today that its **SeptRx® Intrapocket PFO Occluder (IPO)** platform for the percutaneous transcatheter closure of a heart defect known as *patent foramen ovale* (PFO) will be featured at “EuroPCR,” Europe’s most important cardiovascular-focused annual scientific meeting of the year, on Wednesday, May 16th, in Paris.

The Company recently announced completion of enrollment in its InterSEPT™ European clinical trial. The Company intends that human data from its InterSEPT™ clinical trial will be used to apply for CE marking of the SeptRx® IPO device in the second half of 2012, at which time commercial distribution will begin. **The SeptRx® IPO has previously completed a successful 11-patient first-in-human (F-I-H) clinical trial, which demonstrated 100% closure and 100% safety out to 3 years.**

“Being able to present our technology and an update on our clinical trial at such an important cardiovascular meeting as EuroPCR will no doubt fortify our commercialization efforts. We are on schedule for applying for CE mark in the second half of this year,” said **Scott Russell**, SeptRx’s CEO.

PFO is a tunnel-like defect connecting the right atrium with the left atrium. A remnant of fetal circulation, it usually seals itself within a few months after birth. Unfortunately, in about 25% of the population the *PFO* does not fully close and may allow blood (and emboli) to pass directly between the right and left atria. The presence of a *PFO* has been identified as a contributing factor in cryptogenic stroke, chronic migraine, decompression sickness, and obstructive sleep apnea. A *PFO* contributes to these conditions by providing a pathway for emboli (blood clots, air bubbles) in the venous system to reach the arterial system by passing directly from the right atrium to the left.

SeptRx, Inc. is an emerging medical device company that has developed the SeptRx® Intrapocket PFO Occluder (IPO), a platform for the percutaneous transcatheter closure of a heart defect known as patent foramen ovale (PFO).

NOTICE: The SeptRx® IPO is not approved for sale in any regulatory jurisdiction. Further, it is not yet available for investigational use or commercial sale in the U.S.

#####